Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Cellebrite DI Ltd’s stock clocked out at $17.18, up 0.47% from its previous closing price of $17.1. In other words, the price has increased by $0.47 from its previous closing price. On the day, 0.96 million shares were traded. CLBT stock price reached its highest trading level at $17.63 during the session, while it also had its lowest trading level at $17.14.
Ratios:
To gain a deeper understanding of CLBT’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.71 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.40. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 1.93. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 28, 2024, Reiterated its Buy rating but revised its target price to $13.50 from $13 previously.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 11 ’25 when DANA GERNER bought 12,878 shares for $17.53 per share.
AYALA BERLER SHAPIRA bought 2,814 shares of CLBT for $46,741 on Sep 08 ’25. On Sep 02 ’25, another insider, Aliazar Keinan, who serves as the Director of the company, bought 6,847 shares for $16.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLBT now has a Market Capitalization of 4199977472 and an Enterprise Value of 3750126336. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.42 while its Price-to-Book (P/B) ratio in mrq is 10.07. Its current Enterprise Value per Revenue stands at 8.587 whereas that against EBITDA is 50.316.
Stock Price History:
The Beta on a monthly basis for CLBT is 1.28, which has changed by -0.018846393 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, CLBT has reached a high of $26.30, while it has fallen to a 52-week low of $13.10. The 50-Day Moving Average of the stock is 13.53%, while the 200-Day Moving Average is calculated to be -7.20%.
Shares Statistics:
It appears that CLBT traded 1.90M shares on average per day over the past three months and 2244510 shares per day over the past ten days. A total of 239.47M shares are outstanding, with a floating share count of 108.89M. Insiders hold about 54.53% of the company’s shares, while institutions hold 39.89% stake in the company. Shares short for CLBT as of 1756425600 were 5772027 with a Short Ratio of 3.04, compared to 1753920000 on 3634023. Therefore, it implies a Short% of Shares Outstanding of 5772027 and a Short% of Float of 4.78.
Earnings Estimates
The firm’s stock currently is rated by 8.0 analysts. The consensus estimate for the next quarter is $0.14, with high estimates of $0.16 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.52 and $0.45 for the fiscal current year, implying an average EPS of $0.49. EPS for the following year is $0.52, with 8.0 analysts recommending between $0.59 and $0.46.
Revenue Estimates
In the current quarter, 8 analysts expect revenue to total $122.98M. It ranges from a high estimate of $125M to a low estimate of $121M. As of the current estimate, Cellebrite DI Ltd’s year-ago sales were $106.86MFor the next quarter, 8 analysts are estimating revenue of $125.95M. There is a high estimate of $129M for the next quarter, whereas the lowest estimate is $123.17M.
A total of 8 analysts have provided revenue estimates for CLBT’s current fiscal year. The highest revenue estimate was $473M, while the lowest revenue estimate was $465M, resulting in an average revenue estimate of $469.78M. In the same quarter a year ago, actual revenue was $401.2MBased on 8 analysts’ estimates, the company’s revenue will be $548.64M in the next fiscal year. The high estimate is $565.26M and the low estimate is $538.87M.
